Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides.
Synthetic oligodeoxynucleotides (ODN) containing CpG sequences are recognized as a "danger" signal by the immune system of mammals. As a consequence, CpG ODN stimulate innate and adaptive immune responses in humans and a variety of animal species. Indeed, the potential of CpG ODN as therapeutic agents and vaccine adjuvants has been demonstrated in animal models of infectious diseases, allergy and cancer and are currently undergoing clinical trials in humans. While CpG ODN are potent activators of the immune system, their biologic activity is often transient, subsequently limiting their therapeutic application. Modifications in the CpG ODN backbone chemistry, various delivery methods including mixing or cross-linking of ODN to other carrier compounds have been shown to significantly enhance the biologic activity of ODN. However, the exact mechanisms that mediate this enhancement of activity are not well understood and may include local cell recruitment and activation, cytokine production, upregulation of receptor expression and increasing the half-life of ODN through creation of a depot. We will review the various approaches that have been used in enhancing the immunostimulatory effects of CpG ODN in vivo and also discuss the possible mechanisms that may be involved in this enhancement.
Mutwiri
George K
GK
Vaccine and Infectious Disease Organization, 120 Veterinary Road, University of Saskatchewan, Saskatoon, Saskatchewan, Canada S7N 5E3. Mutwiri@sask.usask.ca
Nichani
Anil K
AK
Babiuk
Shawn
S
Babiuk
Lorne A
LA
D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000235:genetics / Q000493:pharmacokinetics; D000818:Animals; D018899:CpG Islands / Q000235:genetics*; D006801:Humans; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage* / Q000235:genetics / Q000493:pharmacokinetics
D000276:Adjuvants, Immunologic; D009838:Oligodeoxyribonucleotides